2 μg CRBN/DDB1 run on 4-12% SDS-PAGE gel under reducing conditions, then visualized with Colloidal Coomassie Blue Stain.

Active, Human, Recombinant CRBN/DDB1, tagged

Enzyme

Product Code: TE3-015

Verified Applications: CRBN/DDB1 is active in ternary complex formation assays using recombinant BRD4 and the degrader molecule dBET1

Activity: Ternary Complex Assay

Purity: 95%

Concentration: 5-15 μM

For Research Use Only (RUO)

Quantity

Clear

Add to Quote

Protein Name: CRBN/DDB1

UniProt #: Q16531;Q96SW2

Predicted Molecular Weight: 53 kDa (CRBN) / 131 kDa (DDB1)

Background and Additional Info

Background: Cereblon (CRBN) is the substrate recognition subunit of the CRL4CRBN cullin E3 ubiquitin ligase complex. It facilitates the ubiquitylation and subsequent proteasomal degradation of proteins including MEIS2, ILF2 and others, and its activity is required for proper limb development. Binding of immunomodulatory drugs (IMiD’s) remodels CRBN’s surface, thereby changing its substrate binding preference. Substrates that are bound by CRBN only in the presence of IMiD’s are known as “neosubstrates.” Expanding CRBN’s neo-substrate scope is a frontier for oncology, neurodegeneration and other research in the field of Targeted Protein Degradation (TPD).

Shipping: The product is shipped with dry ice. Upon receipt, store it immediately at the temperature recommended below.

Storage and Stability: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Aliquot and store ≤ -70°C (stable for 24 months from date of receipt).

Download the Datasheet

References: Liu Y., Bai J., Li D., et al. (2025) Trends Biochem Sci. 50 (2): 134-142. PMID 39753433

Carter T.R., et al. (2024) Bioorg Med Chem. 104: 117699. PMID 38608634

Costacurta M., et al. (2024) FEBS J. 291 (22): 4892-4912 PMID 38975872

Federspiel J.D., et al. (2024) Mol Cell Proteomics 23 (7): 100797 PMID 38866076

Kroupova A., et al. (2024) Nat Commun. 15: 8885. PMID 39406745

Alternate Names: Cereblon, CRBN (MRX69, AD-006)

Protein Sequence: MGHHHHHHHHGSENLYFQSMAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTSLCCKQCQETEITTKNEIFSLSLCGPMAAYVNPHGYVHETLTVYKACNLNLIGRPSTEHSWFPGYAWTVAQCKICASHIGWKFTATKKDMSPQKFWGLTRSALLPTIPDTEDEISPDKVILCL

MWSHPQFEKGGGSGGGSGGSAWSHPQFEKGSLEVLFQGPMSYNYVVTAQKPTAVNGCVTGHFTSAEDLNLLIAKNTRLEIYVVTAEGLRPVKEVGMYGKIAVMELFRPKGESKDLLFILTAKYNACILEYKQSGESIDIITRAHGNVQDRIGRPSETGIIGIIDPECRMIGLRLYDGLFKVIPLDRDNKELKAFNIRLEELHVIDVKFLYGCQAPTICFVYQDPQGRHVKTYEVSLREKEFNKGPWKQENVEAEASMVIAVPEPFGGAIIIGQESITYHNGDKYLAIAPPIIKQSTIVCHNRVDPNGSRYLLGDMEGRLFMLLLEKEEQMDGTVTLKDLRVELLGETSIAECLTYLDNGVVFVGSRLGDSQLVKLNVDSNEQGSYVVAMETFTNLGPIVDMCVVDLERQGQGQLVTCSGAFKEGSLRIIRNGIGIHEHASIDLPGIKGLWPLRSDPNRETDDTLVLSFVGQTRVLMLNGEEVEETELMGFVDDQQTFFCGNVAHQQLIQITSASVRLVSQEPKALVSEWKEPQAKNISVASCNSSQVVVAVGRALYYLQIHPQELRQISHTEMEHEVACLDITPLGDSNGLSPLCAIGLWTDISARILKLPSFELLHKEMLGGEIIPRSILMTTFESSHYLLCALGDGALFYFGLNIETGLLSDRKKVTLGTQPTVLRTFRSLSTTNVFACSDRPTVIYSSNHKLVFSNVNLKEVNYMCPLNSDGYPDSLALANNSTLTIGTIDEIQKLHIRTVPLYESPRKICYQEVSQCFGVLSSRIEVQDTSGGTTALRPSASTQALSSSVSSSKLFSSSTAPHETSFGEEVEVHNLLIIDQHTFEVLHAHQFLQNEYALSLVSCKLGKDPNTYFIVGTAMVYPEEAEPKQGRIVVFQYSDGKLQTVAEKEVKGAVYSMVEFNGKLLASINSTVRLYEWTTEKELRTECNHYNNIMALYLKTKGDFILVGDLMRSVLLLAYKPMEGNFEEIARDFNPNWMSAVEILDDDNFLGAENAFNLFVCQKDSAATTDEERQHLQEVGLFHLGEFVNVFCHGSLVMQNLGETSTPTQGSVLFGTVNGMIGLVTSLSESWYNLLLDMQNRLNKVIKSVGKIEHSFWRSFHTERKTEPATGFIDGDLIESFLDISRPKMQEVVANLQYDDGSGMKREATADDLIKVVEELTRIH